Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
This year's Agnico Eagle Grand Challenge in Cancer Interception has been awarded to Dr. Kathy Han and a team of scientists and clinicians who seek to advance detection of human papilloma virus (HPV) in the bloodstream as a marker of tumor presence and cure more patients with virus-related head and neck, cervical and anal cancers.
Dr. Han's team includes Drs. Scott Bratman, John de Almeida, Ali Hosni, Anna Spreafico, John Kim, John Waldron, Stephanie Lheureux, Wei Xu and Sareh Kesharvarzi.
The goal of the competition is to detect cancers earlier and cure more patients by treating before cancers become too advanced. Dr. Han's work embraces these concepts.
The majority of cervical, anal and some head and neck cancers are caused by HPV and are treated with radiation and chemotherapy, but the cancer often comes back and cannot be detected until it is no longer curable.
Predicting which patients will experience a recurrence is a challenge and their treatment cannot be tailored.
To address this, Dr. Han's project capitalizes on basic cancer biology and pairs it with new cutting-edge genetic technologies.
When the disease recurs, cancer cells grow and die quickly, releasing their DNA into the blood. The DNA from these cancer cells can now be detected in the bloodstream by hunting for HPV genetic material through sensitive laboratory techniques known as liquid biopsy.
Project 'shovel-ready' with patients recruited, samples to analyze
By using two types of this technology (digital polymerase chain reaction, and HPV genome sequencing), Dr. Han's team will be able to distinguish which patients are most at risk of having their cancer return and those who will remain disease free.
Cancer treatments can then be found earlier and treatment tailored with a simple and inexpensive blood test.
"Our team is really honoured to be awarded the Grand Challenge," Dr. Han says. "This award will enable us to validate the accuracy of circulating HPV DNA for detecting residual disease, and make early detection of cancer recurrence and interception a reality."
Their project is "shovel-ready" and has already recruited patients and patient samples to analyze, says Dr. Raymond Kim, Princess Margaret Cancer Centre, Medical Director, Cancer Early Detection.
"Dr. Han's team just published some of their initial work on a smaller set of patients, and her team is poised to take her studies to the next stage with the Agnico Eagle Intercept Cancer Grand Challenge," Dr. Kim says.
"Their team is multi-disciplinary, and features the next generation of cancer researchers. They are focused on HPV cancers which affects a wide range of patients, particularly under-represented populations, and will make cancer early detection and interception a reality."
The Grand Challenges are a series of bold, innovative and high-impact projects at the Princess Margaret. They aim to advance cancer diagnoses and treatments to cure more patients and improve quality of life by moving beyond chemotherapy.
The series focuses on four key directives: